Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $9.62 and last traded at $9.64, with a volume of 181,083 shares. The stock had previously closed at $8.87.

Separately, HC Wainwright set a $25.00 price target on shares of Oramed Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, May 22nd.

The stock’s market cap is $129.06 million. The stock has a 50 day moving average of $8.19 and a 200-day moving average of $7.45.

In other Oramed Pharmaceuticals news, Director Xiaopeng Li bought 89,636 shares of the company’s stock in a transaction dated Wednesday, August 2nd. The shares were bought at an average price of $8.50 per share, for a total transaction of $761,906.00. Following the acquisition, the director now directly owns 206,350 shares of the company’s stock, valued at $1,753,975. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 27.50% of the stock is owned by corporate insiders.

A hedge fund recently bought a new stake in Oramed Pharmaceuticals stock. Virtu KCG Holdings LLC bought a new stake in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 16,077 shares of the biotechnology company’s stock, valued at approximately $125,000. Virtu KCG Holdings LLC owned 0.12% of Oramed Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 1.34% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Oramed Pharmaceuticals Inc. (ORMP) Reaches New 52-Week High at $9.62” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.dailypolitical.com/2017/09/06/oramed-pharmaceuticals-inc-ormp-reaches-new-52-week-high-at-9-62.html.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.